Form 4: Mineralys Director Sells MLYS Shares After Option Exercise

Mineralys Therapeutics Director Daphne Karydas exercised stock options and subsequently sold all 15,000 acquired shares for a significant gain.

Summary

• Daphne Karydas, a Director of Mineralys Therapeutics, Inc. (MLYS), reported transactions on November 13, 2025.
• Karydas exercised 15,000 stock options at an exercise price of $10.20 per share, acquiring 15,000 shares of common stock.
• Immediately following the exercise, Karydas sold all 15,000 acquired shares in two separate transactions.
• The first sale involved 10,115 shares at a weighted-average price of $45.8083, with prices ranging from $45.19 to $46.18.
• The second sale involved 4,885 shares at a weighted-average price of $46.3554, with prices ranging from $46.19 to $46.70.
• Following these transactions, Karydas's direct beneficial ownership of common stock from these specific transactions is 0 shares.
• Karydas still beneficially owns 17,900 stock options.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to the significant personal gain realized by the director, reflecting the value of the company's stock. However, the immediate sale of all acquired shares could introduce a slight neutral-to-negative sentiment for some investors.

Positives

• The director realized a substantial gross profit of approximately $536,895.08 from the exercise and immediate sale of 15,000 shares (total proceeds of $689,895.08 minus exercise cost of $153,000).
• The transactions demonstrate the value of the company's equity compensation plan for its directors.

Negatives

• The immediate sale of all 15,000 shares acquired through option exercise by a director could be interpreted by some investors as a lack of confidence in the company's near-term stock price appreciation, although it is a common practice for managing personal finances and diversifying holdings.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This filing reports an individual insider transaction and does not provide broader industry context or trends.

Stakeholder Impact

• Shareholders: May view the director's full sale of acquired shares with mixed feelings; some might see it as a normal liquidity event, while others might question the director's long-term conviction.
• Director (Daphne Karydas): Benefited significantly from the exercise of options and subsequent sale, realizing a substantial personal gain.

Key Dates

Keywords

Mineralys Therapeutics, MLYS, Form 4, Insider Trading, Stock Option, Share Sale, Director Transaction, Daphne Karydas